- Home
- EDRY vs OCX Comparison
EDRY vs OCX Comparison
Compare EDRY & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- OCX
- Stock Information
- Founded
- EDRY 2018
- OCX 2009
- Country
- EDRY Greece
- OCX United States
- Employees
- EDRY N/A
- OCX N/A
- Industry
- EDRY Marine Transportation
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EDRY Consumer Discretionary
- OCX Health Care
- Exchange
- EDRY Nasdaq
- OCX Nasdaq
- Market Cap
- EDRY 38.5M
- OCX 35.1M
- IPO Year
- EDRY N/A
- OCX N/A
- Fundamental
- Price
- EDRY $11.38
- OCX $2.08
- Analyst Decision
- EDRY
- OCX Buy
- Analyst Count
- EDRY 0
- OCX 3
- Target Price
- EDRY N/A
- OCX $4.42
- AVG Volume (30 Days)
- EDRY 11.1K
- OCX 69.1K
- Earning Date
- EDRY 02-13-2025
- OCX 11-12-2024
- Dividend Yield
- EDRY N/A
- OCX N/A
- EPS Growth
- EDRY N/A
- OCX N/A
- EPS
- EDRY N/A
- OCX N/A
- Revenue
- EDRY $65,085,280.00
- OCX $709,000.00
- Revenue This Year
- EDRY $34.61
- OCX N/A
- Revenue Next Year
- EDRY $15.93
- OCX $106.34
- P/E Ratio
- EDRY N/A
- OCX N/A
- Revenue Growth
- EDRY 39.04
- OCX N/A
- 52 Week Low
- EDRY $10.04
- OCX $1.97
- 52 Week High
- EDRY $24.84
- OCX $3.48
- Technical
- Relative Strength Index (RSI)
- EDRY 43.15
- OCX 37.86
- Support Level
- EDRY $11.43
- OCX $2.05
- Resistance Level
- EDRY $11.80
- OCX $2.24
- Average True Range (ATR)
- EDRY 0.50
- OCX 0.21
- MACD
- EDRY 0.21
- OCX -0.00
- Stochastic Oscillator
- EDRY 66.22
- OCX 15.28
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.